Skip to main content
. 2008 Dec 15;27(4):579–584. doi: 10.1200/JCO.2008.18.9639

Fig 2.

Fig 2.

Survival by Kaplan-Meier analysis, comparing the current study with erlotinib plus temozolomide to the historical control studies. The hazard ratio is corrected for age, Karnofsky Performance Score, and extent of resection. Hazard ratio = 0.64 (95% CI, 0.45 to 0.91; P = .01). OS, overall survival.